Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

 Back to index

Cancer Chemotherapy Regimen for Breast Cancer


 AC/ACMF                                             breast(17,18)
 _________________________________________________________________
  adriamycin...... 40 mg/sqm IV day 1.
  cytoxan......... 1 g/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 21 days.

  adriamycin...... 40 mg/sqm IV day 1.
  cytoxan......... 1 g/sqm IV day 1.
  methotrexate.... 30 to 40 mg/sqm IV days 21, 28 and 35.
  fluorouracil.... 400 to 600 mg/sqm IV days 21, 28 and 35.
  FREQUENCY....... Repeat cycle every 42 days.

   17. Boston B, et.al. Combination vs. combination sequential 
       non-hormonal chemotherapy in advanced breast cancer. Proc Am 
       Soc Clin Oncol 17:247, 1976.

  reference...
    Kennealey GT.  Boston B.  Mitchell MS.  Knobf MK.  Bobrow SN.  
    Pezzimenti JF.  Lawrence R.  Bertino JR. Combination 
    chemotherapy for advanced breast cancer: two regimens 
    containing adriamycin. Cancer.  42(1):27-33, 1978 Jul. 
  abstract...
    Forty-eight women with advanced metastatic carcinoma of the 
    breast were treated with one of two combination chemotherapy 
    regimens: 1) adriamycin and cyclophosphamide or 2) adriamycin, 
    cyclophosphamide, methotrexate and 5-fluorouracil. The 
    response rate in the two-drug treatment group was 50% and in 
    the four-drug treatment group, 55%. The median duration of 
    response was ten months in both treatment groups. Dramatic 
    responses were seen in patients with visceral metastases. 
    Patients who responded to chemotherapy had a significantly 
    longer survival than nonresponders (p less than 0.01). The 
    long interval between adriamycin doses (six weeks) in the four 
    drug regimen did not adversely effect the response rate--an 
    important finding in view of the dose-related cardiac toxicity 
    of this agent. 
advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application



 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.